Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Brooke Army Medical Center GlaxoSmithKline Becton, Dickinson and Company |
---|---|
Information provided by: | Brooke Army Medical Center |
ClinicalTrials.gov Identifier: | NCT00289588 |
The main purpose of this study is to determine if applying mupirocin into soldiers noses who are colonized with methicillin-resistant Staphylococcus aureus (MRSA) will reduce infections in them and their cohort of fellow soldiers.
Condition | Intervention |
---|---|
Community-Acquired MRSA Infections Abscesses Cellulitis Folliculitis |
Drug: Mupirocin (drug) |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus Infection in Soldiers: a Controlled Trial |
Estimated Enrollment: | 3000 |
Study Start Date: | January 2005 |
Estimated Study Completion Date: | December 2005 |
Community-acquired MRSA infections are increasingly common in the community and in particular among certain groups of which soldiers are one. Many researchers and clinicians have postulated that one method to prevent infections is to selectively eradicate CA-MRSA in those who are colonized with the pathogen. The two main purposes of the study are: to determine if selective CA-MRSA eradication in subjects reduces infections in the CA-MRSA colonized individual; and to determine if selective CA-MRSA eradication in subjects reduces infections in the study cohort. Other information concerning CA-MRSA includes: prevalence, risk factors, and virulence data. The population will be soldiers enrolled in the combat medic training class at Ft. Sam Houston. We will enroll approximately 3000 soldiers over a two year period. After informed written consent, we will culture their anterior nares nares and administer questionnaires at the beginning and at the end of the study, following them prospectively for infections. The follow-up period will be 16 weeks. For those with CA-MRSA in their nares, they will be randomized (by cohort) to receive either 5 days of mupirocin or placebo.
Ages Eligible for Study: | 17 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:Soldiers enrolled into the combat medic course at Ft. Sam Houston, TX.
-
Exclusion Criteria: Allergy to mupirocin.
-
United States, Texas | |
Brooke Army Medical Center | |
Ft. Sam Houston, Texas, United States, 78234 |
Principal Investigator: | Michael W Ellis, MD | Brooke Army Medical Center |
Study ID Numbers: | C.2004.163 |
Study First Received: | February 9, 2006 |
Last Updated: | February 13, 2006 |
ClinicalTrials.gov Identifier: | NCT00289588 |
Health Authority: | United States: Federal Government |
Methicillin-resistant Staphylococcus aureus Staphylococcus aureus MRSA CA-MRSA |
Bacterial Infections Mupirocin Skin Diseases Inflammation Staphylococcal Infections Cellulitis Skin Diseases, Infectious |
Gram-Positive Bacterial Infections Methicillin Abscess Connective Tissue Diseases Suppuration Folliculitis |
Hair Diseases Anti-Infective Agents Anti-Bacterial Agents Communicable Diseases |
Pathologic Processes Therapeutic Uses Infection Pharmacologic Actions |